Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer's DiseaseGlobeNewsWire • 11/04/20
Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020GlobeNewsWire • 09/30/20
Does Cassava Sciences Have the Alzheimer's Disease Drug We've Been Waiting For?The Motley Fool • 09/20/20
Alzheimer’s News: Cassava Sciences Stock on the Move Following Drug Trial ResultsInvestorPlace • 09/15/20
How Cassava Sciences Could Be Pioneering A Groundbreaking Alzheimer’s Treatment24/7 Wall Street • 09/14/20
Cassava Sciences rockets on heavy volume after Alzheimer's drug trial results prompts analyst upgradeMarket Watch • 09/14/20
Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer’s DiseaseGlobeNewsWire • 09/14/20
Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ETGlobeNewsWire • 09/11/20
Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20